COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
RVAC Medicines Pte. Ltd.
RVM-V001- mRNA COVID-19 vaccine candidate
Phase 1 study of RVM-V001 was initiated- reported on Sep.21, 2022.
Moat Biotechnology Corporation
Intranasal COVID-19 vaccine
Results from the phase 1 study showed that intranasal Covid-19 vaccine was safe and well tolerated in the initial ascending dose cohorts. In addition, a booster dose of the vaccine induced strong neutralizing antibody responses- reported on Sept. 20, 2022.
Omeros Corp.
Results from the narsoplimab arm of the I-SPY COVID Trial showed that addition of narsoplimab to treatment of critically ill patients with COVID-19 reduced the mortality risk. Narsoplimab showed the largest reduction in mortality risk to date across all drugs reported from the I-SPY COVID trial- reported on Sept.15, 2022.
Quantum Leap Healthcare Collaborative
Revive Therapeutics Ltd.
A revised protocol for the Phase 3 study of Bucillamine to treat patients with mild to moderate COVID-19 was submitted to the FDA- reported on Sept 14, 2022.
Phase 2 study evaluating PBI-0451 for the treatment and prevention of SARS-CoV-2 infections was initialed- reported on Sept. 13, 2022.
Avacc 10- intranasal Covid-19 vaccine candidate
Additional favorable preclinical and toxicology data for Avacc 10, including reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern were announced on Sept. 12, 2022
Phase I study to start in the fourth quarter of 2022
Elicio Therapeutics
ELI-005- Covid-19 vaccine
Data from the preclinical study showed that ELI-005 elicits strong and long-lasting cellular and humoral immune responses that were maintained at significantly higher levels than comparator vaccines over 32 weeks in mice- reported on July 06, 2022.

Preclinical study
Sinovac Biotech Ltd.
COVID-19 Vaccine against Ómicron strain
Chilean Public Health Institute has cleared Phase 2 study of COVID-19 Vaccine against Omicron strain- reported on Sept. 6, 2022.

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Seffner, Florida -based Canyon Furniture Co. is recalling ladders sold with bunk bed and hutch sets citing entrapment and strangulation risks, the U.S. Consumer Product Safety Commission said. The about 2,100 units of Canyon Lake and Cottage Colors Bunk Bed and Hutch Sets were sold exclusively at Rooms To Go. Lyft announced the expansion to its partnership with Indeed in Jobs Access program. The ride-hailing company will be providing transportation access for Indeed's Ready to Work program. Indeed's Ready to Work program is a series of free virtual and in-person events for job seekers in several cities across the U.S. from September 15 to October 8, 2022. Pool and Spa drain covers imported to the United States by various companies have been recalled due to violation of the Virginia Graeme Baker Pool and Spa Safety Act, the U.S. Consumer Product Safety Commission announced. The various recalls include pool and spa drain covers manufactured in China and sold exclusively at Amazon.com for different prices ranging from $10 to $12.